2026

>

Prolonged response to osimertinib in EGFR exon 20 insertion and SETD2 loss-of-function mutation in advanced NSCLC: a molecular paradox

>

Tako-Tsubo syndrome after alectinib initiation

>

Long-term survivor with advanced small-cell lung carcinoma: the role of maintenance immunotherapy and local treatment of oligoprogression

>

Clinical-radiological discordance after neoadjuvant chemoimmunotherapy in resectable lung squamous cell carcinoma

>

Cardiac tamponade as the initial presentation of metastatic lung adenocarcinoma with high PD-L1 expression

>

EGFR appears to be, and BRAF may be too

>

Beyond 0%: durable response to chemoimmunotherapy in PD-L1-negative non-small cell lung cancer

>

PD-L1 after neoadjuvant therapy: an adjuvant treatment dilemma

>

Clinical challenges in the management of stage III EGFRmutated non-small cell lung cancer: integrating surgery and adjuvant therapy in the post-ADAURA era

>

ALK metamorphosis: a diagnostic and therapeutic challenge